InflaRx News

InflaRx's Promising Future: Buy Rating Reaffirmed Amidst Pipeline Progress and Upcoming R&D Insights

TipRanksMay 10 01:28 ET

InflaRx Analyst Ratings

BenzingaMay 9 06:51 ET

InflaRx Buy Rating: Strong Financials and High Potential of Gohibic for PG Treatment

TipRanksMay 9 06:28 ET

LifeSci Capital Remains a Hold on InflaRx (IFRX)

TipRanksMay 8 16:45 ET

LifeSci Capital Reaffirms Their Hold Rating on InflaRx (IFRX)

TipRanksMar 22 15:05 ET

InflaRx Analyst Ratings

BenzingaMar 22 08:16 ET

Buy Rating Justified for InflaRx Despite Earnings Miss: Financial Stability and INF904's Market Potential

TipRanksMar 22 06:16 ET

InflaRx Analyst Ratings

BenzingaJan 25 11:23 ET

Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), InflaRx (IFRX) and Eli Lilly & Co (LLY)

TipRanksJan 9 01:30 ET

InflaRx's Promising INF904 Phase 1 Results Prompt Buy Rating

TipRanksJan 5 06:28 ET

InflaRx (IFRX) Gets a Hold From LifeSci Capital

TipRanksJan 4 16:35 ET

Buy Rating for InflaRx: Potential Breakthrough PG Treatment and Promising Revenue Forecasts

TipRanksNov 6, 2023 10:16 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: InflaRx (IFRX), Exelixis (EXEL) and Humana (HUM)

TipRanksNov 6, 2023 01:50 ET

Analysts Offer Insights on Healthcare Companies: Cross Country Healthcare (CCRN), InflaRx (IFRX) and Elevation Oncology (ELEV)

TipRanksNov 2, 2023 15:01 ET

InflaRx Analyst Ratings

BenzingaNov 2, 2023 12:23 ET

LifeSci Capital Sticks to Its Hold Rating for InflaRx (IFRX)

TipRanksNov 1, 2023 15:25 ET

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), InflaRx (IFRX)

TipRanksSep 12, 2023 06:20 ET

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $9 Price Target

BenzingaSep 12, 2023 06:10 ET

InflaRx Analyst Ratings

BenzingaSep 12, 2023 06:10 ET

LifeSci Capital Keeps Their Buy Rating on InflaRx (IFRX)

TipRanksSep 11, 2023 18:25 ET